Although formal, widely adopted guidelines for anti-TNF-α discontinuation in pediatric JIA are lacking, some pediatric rheumatology working groups have suggested tapering approaches or structured monitoring after biologic cessation; however, these recommendations are heterogeneous and not standardized in terms of timing, patient selection, or follow-up protocols [8]. Here, TNF is linked to juvenile idiopathic arthritis.